Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S75-81. doi: 10.1007/s00259-007-0705-x.

Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography.

Author information

Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstrasse 22, München, Germany.



The proof of concept for in vivo targeting of beta-amyloid plaques (Abeta) in patients with Alzheimer's disease (AD) by means of nuclear imaging methods has been shown in recent clinical studies.


For positron emission tomography (PET), the five compounds [(11)C]PIB, 3'[(18)F]FPIB, [(18)F]FDDNP, [(11)C]SB-13 and [(18)F]F-SB-13 have been developed by a formal charge neutralisation of agents used for staining of AD brain post mortem.


In AD-patients, these compounds have been shown to possess a selective uptake in the brain regions known to have a high Abeta-load. Progress towards tracers with proportionality between tracer uptake and quantity of Abeta-load, of use for longitudinal studies of AD patients, is addressed in the current development of Abeta-tracers.


Despite the extensive information on the structure-affinity relationship of several Abeta-binding compounds, data on the regional brain binding kinetics-beyond uptake in healthy rodents-have been obtained only for a few compounds. Recent results indicate that PET-imaging of Abeta-deposits in transgenic rodent models of AD is feasible which may be valuable for a more relevant preclinical evaluation of Abeta-tracers.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center